Sep 30, 2021 / 12:00PM GMT
Carvey Leung - Cantor Fitzgerald - Analyst
Good morning, everyone. My name is Carvey Leung, an associate on Louise Chen's large-cap and biopharma equity research team here at Cantor. Thank you for joining us today for our virtual fireside chat with Aquestive Therapeutics.
Aquestive is a pharma company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally developed proprietary product to date, Sympazan oral film, has a commercial proprietary pipeline focused on the treatment of diseases of the central nervous system and other unmet needs. And the Company is also developing orally administered complex molecules to provide alternatives to invasively administered standard of care treatments.
We are very excited to have Keith Kendall, CEO; Ernie Toth, CFO; and Dan Barber, COO of Aquestive with us today to discuss the Company.
Questions and Answers:
Carvey Leung - Cantor Fitzgerald - AnalystWell, first of all, welcome. And for the investors that are